Global Oncolytic Virus Immunotherapy Market, By Type (Vaccinia Virus, Herpes Simplex Virus, Reovirus, Adenovirus, Others), Application (Non-small Cell Lung Cancer (NSCLC), Melanoma, Breast Cancer, Pancreatic Cancer, Others), Route of Administration (Intravenous, Intratumoral, Other), End-Users (Clinic, Hospital, Cancer Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Global Oncolytic Virus Immunotherapy Market
Global oncolytic virus immunotherapy market is expected to gain market growth in the forecast period 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 12% in the above mentioned forecast period.
Oncolytic virus immunotherapy works by involving the use of viruses to infect and eliminate the cancerous cells. Oncolytic virus has decreased ability to infect the healthy cells and deliver therapeutic payloads to tumor cells. As a result it increases the production of immune-boosting molecules. Post infection, oncolytic viruses causing the bursting of cancer cells and eventually eradicating the cells. This results in the release of cancer antigens which further stimulate the immune response.
Rise in the prevalence of cancer disease, growing healthcare expenditure, rising initiatives by the government and non-government organisations for spreading awareness about the rapid diagnosis and treatment of different type of cancer, advancement in technologies and growing government funding are the factors that will expand the oncolytic virus immunotherapy market. Rise in the research and development activities and increase in the demand for emerging economies will provide beneficial opportunities for the oncolytic virus immunotherapy market in the forecast period of 2021-2028.
However, high cost of medication and lack of awareness among people about the treatment and diagnostic methods are the factors that will hinder the market growth and will further challenge the oncolytic virus immunotherapy market in the forecast period mentioned above.
This oncolytic virus immunotherapy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the oncolytic virus immunotherapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Oncolytic Virus Immunotherapy Market Scope and Market Size
The oncolytic virus immunotherapy market is segmented on the basis of type, application, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the oncolytic virus immunotherapy market is segmented into vaccinia virus, herpes simplex virus, reovirus, adenovirus and others.
- On the basis of application, the oncolytic virus immunotherapy market is segmented into non-small cell lung cancer (NSCLC), melanoma, breast cancer, pancreatic cancer and others.
- On the basis of route of administration, the oncolytic virus immunotherapy market is segmented into intravenous, intratumoral and others.
- On the basis of end-users, the oncolytic virus immunotherapy market is segmented into clinic, hospital, cancer research institutes and others.
The oncolytic virus immunotherapy market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Oncolytic Virus Immunotherapy Market Country Level Analysis
Oncolytic virus immunotherapy market is analyzed and market size information is provided by the country, type, application, route of administration, end-users and distribution channel as referenced above.
The countries covered in the oncolytic virus immunotherapy market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the oncolytic virus immunotherapy market due to the presence of major key players, well-developed healthcare sector and high prevalence of cancer in this region. Asia-Pacific is expected to grow during the forecast period 2021 to 2028 due to the increasing research and development activities, emerging markets, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Oncolytic virus immunotherapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Oncolytic Virus Immunotherapy Market Share Analysis
Oncolytic virus immunotherapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to oncolytic virus immunotherapy market.
The major players covered in the oncolytic virus immunotherapy market report are Amgen Inc. TILT Biotherapeutics Ltd, Oncorus, Inc., Merck Sharp & Dohme Corp., Replimune Group Inc., Oncolys BioPharma Inc., Sorrento Therapeutics, Inc., Oncolytics Biotech, Inc., and SillaJen, Inc., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.